Gene Therapy, ASOs, and Beyond: What’s Coming for Huntington’s Disease
ADDRESS-LC Study of Long COVID Initiated, Phase 4 Trial Testing IVIg Transition to Efgartigimod, Lack of Rebound Effect Seen in Ozanimod
CMSC Live: 2025 Annual Meeting Day 3
NeurologyLive® Friday 5 — May 30, 2025